A 32-year-old woman from rural India presents to the gynecology clinic with abnormal vaginal bleeding. Pap smear screening shows atypical squamous cells of undetermined significance (ASCUS). What is the most appropriate next investigation to determine the need for colposcopy?

## Investigation of ASCUS on Pap Smear **Key Point:** HPV DNA testing (specifically high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) is the gold standard reflex test for ASCUS cytology. It has high negative predictive value and guides colposcopy referral. ### Rationale for HPV Testing **High-Yield:** ASCUS represents a gray zone in cytology (5–10% of Pap smears). HPV DNA testing stratifies risk: - **HPV-positive ASCUS** → 20–30% risk of CIN2+ → proceed to colposcopy - **HPV-negative ASCUS** → <5% risk of CIN2+ → routine screening ### Why HPV DNA Testing is Superior | Feature | HPV DNA Testing | Repeat Pap Smear | Direct Colposcopy | |---------|-----------------|------------------|-------------------| | Sensitivity for CIN2+ | 95–99% | Lower; requires repeat | 100% but over-referral | | Specificity | ~90% | Variable | Lower (unnecessary colposcopy) | | Cost-effectiveness | High | Delays diagnosis | High cost, patient anxiety | | Clinical utility | Guides triage | Delays management | Unnecessary procedures | **Clinical Pearl:** HPV-negative women with ASCUS can safely return to routine screening (every 3 years), avoiding unnecessary colposcopy and reducing patient anxiety. **Mnemonic:** **ASCUS → HPV** — *Always Screen Cytology Uncertainty with HPV* testing. ### Management Algorithm ```mermaid flowchart TD A[ASCUS on Pap Smear]:::outcome --> B{HPV DNA Testing}:::decision B -->|HPV-positive| C[Colposcopy with biopsy if indicated]:::action B -->|HPV-negative| D[Routine screening in 3 years]:::action C --> E{Biopsy Result}:::decision E -->|CIN1| F[Observation or ablation]:::action E -->|CIN2/3| G[Excisional treatment]:::action E -->|Normal| H[Return to routine screening]:::action ``` [cite:Park 26e Ch 8]